Clinical Trials Browser

INDUSTRY × HBI-8000 × Clear all

NCT05141357 2025-12-24

HBI-8000

Phase 2 Terminated

5 enrolled 8 charts

Carcinoma, Non-Small-Cell Lung

NCT04674683 2025-09-24

Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma

Phase 3 Active not recruiting

CNSDermatologic

Brain Neoplasms, Melanoma

NCT05770882 2025-03-11

Chidamide + Regorafenib in Hepatocellular Carcinoma (HCC)

Phase 1/2 Terminated

Gastrointestinal

Carcinoma, Hepatocellular

NCT05833724 2025-03-11

Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)

Phase 2 Recruiting

Recurrence, Lymphoma, T-Cell, Peripheral

NCT02953652 2024-09-19

Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Phase 2 Completed

55 enrolled 18 charts

Lymphoma, T-Cell, Peripheral

NCT02955589 2024-09-19

Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Adult T Cell Lymphoma (ATL)

Phase 2 Completed

23 enrolled 15 charts

LymphoidOther hematologic neoplasm

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT02718066 2023-11-09

Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer

Phase 1/2 Completed

DermatologicGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma

NCT02569489 2022-07-18

Dose Escalation Study of HBI-8000 in Combination With Paclitaxel and Trastuzumab in Women With Advanced or Metastatic HER2+ Breast Cancer

Phase 1 Withdrawn

Breast Neoplasms

NCT02697552 2017-01-12

Safety Study of HBI-8000 in Japanese Patients With Non Hodgkin's Lymphoma

Phase 1 Completed

Lymphoma, Non-Hodgkin